Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes - PubMed (original) (raw)
doi: 10.1038/nbt.1759. Epub 2011 Jan 23.
Carsten Hopf, Mikhail M Savitski, Antje Dittmann, Paola Grandi, Anne-Marie Michon, Judith Schlegl, Yann Abraham, Isabelle Becher, Giovanna Bergamini, Markus Boesche, Manja Delling, Birgit Dümpelfeld, Dirk Eberhard, Carola Huthmacher, Toby Mathieson, Daniel Poeckel, Valérie Reader, Katja Strunk, Gavain Sweetman, Ulrich Kruse, Gitte Neubauer, Nigel G Ramsden, Gerard Drewes
Affiliations
- PMID: 21258344
- DOI: 10.1038/nbt.1759
Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
Marcus Bantscheff et al. Nat Biotechnol. 2011 Mar.
Abstract
The development of selective histone deacetylase (HDAC) inhibitors with anti-cancer and anti-inflammatory properties remains challenging in large part owing to the difficulty of probing the interaction of small molecules with megadalton protein complexes. A combination of affinity capture and quantitative mass spectrometry revealed the selectivity with which 16 HDAC inhibitors target multiple HDAC complexes scaffolded by ELM-SANT domain subunits, including a novel mitotic deacetylase complex (MiDAC). Inhibitors clustered according to their target profiles with stronger binding of aminobenzamides to the HDAC NCoR complex than to the HDAC Sin3 complex. We identified several non-HDAC targets for hydroxamate inhibitors. HDAC inhibitors with distinct profiles have correspondingly different effects on downstream targets. We also identified the anti-inflammatory drug bufexamac as a class IIb (HDAC6, HDAC10) HDAC inhibitor. Our approach enables the discovery of novel targets and inhibitors and suggests that the selectivity of HDAC inhibitors should be evaluated in the context of HDAC complexes and not purified catalytic subunits.
Comment in
- Chemoproteomics quantifies complexity.
Holson EB, Schreiber SL. Holson EB, et al. Nat Biotechnol. 2011 Mar;29(3):235-6. doi: 10.1038/nbt.1804. Nat Biotechnol. 2011. PMID: 21390028 No abstract available.
Similar articles
- Chemoproteomics quantifies complexity.
Holson EB, Schreiber SL. Holson EB, et al. Nat Biotechnol. 2011 Mar;29(3):235-6. doi: 10.1038/nbt.1804. Nat Biotechnol. 2011. PMID: 21390028 No abstract available. - Chemoproteomics reveals time-dependent binding of histone deacetylase inhibitors to endogenous repressor complexes.
Becher I, Dittmann A, Savitski MM, Hopf C, Drewes G, Bantscheff M. Becher I, et al. ACS Chem Biol. 2014 Aug 15;9(8):1736-46. doi: 10.1021/cb500235n. Epub 2014 Jun 6. ACS Chem Biol. 2014. PMID: 24877719 - Acetylation site specificities of lysine deacetylase inhibitors in human cells.
Schölz C, Weinert BT, Wagner SA, Beli P, Miyake Y, Qi J, Jensen LJ, Streicher W, McCarthy AR, Westwood NJ, Lain S, Cox J, Matthias P, Mann M, Bradner JE, Choudhary C. Schölz C, et al. Nat Biotechnol. 2015 Apr;33(4):415-23. doi: 10.1038/nbt.3130. Epub 2015 Mar 9. Nat Biotechnol. 2015. PMID: 25751058 - Histone deacetylase 10: A polyamine deacetylase from the crystal structure to the first inhibitors.
Lambona C, Zwergel C, Fioravanti R, Valente S, Mai A. Lambona C, et al. Curr Opin Struct Biol. 2023 Oct;82:102668. doi: 10.1016/j.sbi.2023.102668. Epub 2023 Aug 4. Curr Opin Struct Biol. 2023. PMID: 37542907 Review. - Inside HDAC with HDAC inhibitors.
Bertrand P. Bertrand P. Eur J Med Chem. 2010 Jun;45(6):2095-116. doi: 10.1016/j.ejmech.2010.02.030. Epub 2010 Feb 14. Eur J Med Chem. 2010. PMID: 20223566 Review.
Cited by
- A Probe-Free Occupancy Assay to Assess a Targeted Covalent Inhibitor of Receptor Tyrosine-Protein Kinase erbB-2.
Xue L, van Kalken D, James EM, Giammo G, Labenski MT, Cantin S, Fahnoe K, Worm K, Wang Z, Corin AF. Xue L, et al. ACS Pharmacol Transl Sci. 2024 Aug 1;7(8):2507-2515. doi: 10.1021/acsptsci.4c00326. eCollection 2024 Aug 9. ACS Pharmacol Transl Sci. 2024. PMID: 39144565 - De novo missense variants in HDAC3 leading to epigenetic machinery dysfunction are associated with a variable neurodevelopmental disorder.
Yoon JG, Lim SK, Seo H, Lee S, Cho J, Kim SY, Koh HY, Poduri AH, Ramakumaran V, Vasudevan P, de Groot MJ, Ko JM, Han D, Chae JH, Lee CH. Yoon JG, et al. Am J Hum Genet. 2024 Aug 8;111(8):1588-1604. doi: 10.1016/j.ajhg.2024.06.015. Epub 2024 Jul 23. Am J Hum Genet. 2024. PMID: 39047730 Free PMC article. - Single-cell EpiChem jointly measures drug-chromatin binding and multimodal epigenome.
Dong C, Meng X, Zhang T, Guo Z, Liu Y, Wu P, Chen S, Zhou F, Ma Y, Xiong H, Shu S, He A. Dong C, et al. Nat Methods. 2024 Sep;21(9):1624-1633. doi: 10.1038/s41592-024-02360-0. Epub 2024 Jul 18. Nat Methods. 2024. PMID: 39025969 Free PMC article. - Chromatin context-dependent effects of epigenetic drugs on CRISPR-Cas9 editing.
Schep R, Trauernicht M, Vergara X, Friskes A, Morris B, Gregoricchio S, Manzo SG, Zwart W, Beijersbergen RL, Medema RH, van Steensel B. Schep R, et al. Nucleic Acids Res. 2024 Aug 27;52(15):8815-8832. doi: 10.1093/nar/gkae570. Nucleic Acids Res. 2024. PMID: 38953163 Free PMC article. - The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods.
Curcio A, Rocca R, Alcaro S, Artese A. Curcio A, et al. Pharmaceuticals (Basel). 2024 May 10;17(5):620. doi: 10.3390/ph17050620. Pharmaceuticals (Basel). 2024. PMID: 38794190 Free PMC article. Review.
References
- Cell. 2007 Feb 23;128(4):693-705 - PubMed
- Curr Opin Genet Dev. 2008 Oct;18(5):404-10 - PubMed
- Cell. 2009 Dec 11;139(6):1029-31 - PubMed
- Nat Rev Drug Discov. 2006 Sep;5(9):769-84 - PubMed
- J Proteome Res. 2009 Oct;8(10):4743-52 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases